T-20 continues to look promising.
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D017322:Clinical Trials, Phase II as Topic; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000187:drug effects* / Q000494:pharmacology / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; D000077560:Enfuvirtide